drugset / Trial / NCT01493726

A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia

NCT01493726

Phase 1 Completed 88 enrolled Alkermes, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will determine the pharmacokinetics (PK), safety, and tolerability of ALKS 9072 (also known as ALKS 9070) after 4 monthly doses in adults with chronic stable schizophrenia.

Timeline

Start
2011-12
Primary completion
2013-06
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Aripiprazole Lauroxil Small molecule Intramuscular

Indications